Almitas Capital LLC Lyell Immunopharma, Inc. Transaction History
Almitas Capital LLC
- $177 Million
- Q1 2025
A detailed history of Almitas Capital LLC transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Almitas Capital LLC holds 2,482,606 shares of LYEL stock, worth $22.7 Million. This represents 0.76% of its overall portfolio holdings.
Number of Shares
2,482,606
Previous 1,050,520
136.32%
Holding current value
$22.7 Million
Previous $672,000
99.4%
% of portfolio
0.76%
Previous 0.33%
Shares
2 transactions
Others Institutions Holding LYEL
# of Institutions
117Shares Held
175MCall Options Held
2.9KPut Options Held
6K-
Mwg Management Ltd. Washington, DC20.2MShares$184 Million18.54% of portfolio
-
Foresite Capital Management Iv, LLC Larkspur, CA16MShares$146 Million9.84% of portfolio
-
Apoletto LTD Washington, DC15.1MShares$138 Million42.56% of portfolio
-
Orland Properties LTD Washington, DC15.1MShares$138 Million9.84% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$123 Million0.0% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $2.27B
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...